Intradialytic Benson's Relaxation Technique in Patients With Chronic Kidney Disease

November 9, 2026 updated by: Manar Tarek Mostafa Morsy, Cairo University

Intradialytic Benson's Relaxation Technique on Dialysis Adequacy and Sleep Quality in Patients With Chronic Kidney Disease

The purpose of this study is to determine the impact of benson's relaxation technique on dialysis adequacy and sleep quality among CKD patients.

The intervention will include intradialytic benson's relaxation sessions, and outcomes such dialysis adequacy and sleep quality will be evaluated after 12 weeks of benson's relaxation technique in patients with CKD.

Study Overview

Detailed Description

A major public health concern, chronic kidney disease is characterized by abnormalities of kidney structure or function that have been present for more than three months and have particular health consequences . Uremia is a clinical condition associated with declining renal function and is characterized by fluid overload, electrolyte imbalances, metabolic abnormalities, and physiological changes. Urea exhibits direct and indirect toxicity to various tissues leading to symptoms such as nausea, vomiting, fatigue, anorexia, muscle cramps, pruritus, and altered mentation.Previous studies reported that poor sleep is one of the most prevalent symptoms experienced by CRD patients most patients because of increase toxins concentrations of plasma (creatinine and urea), anemia, nocturnal hypoxia, and co-morbidities. Benson's relaxation technique is an effective intervention which has been introduced as useful non-pharmacological method which decreases stress over its effect on mental, physical conditions, depression, anxiety, self-steam, enhance sleep and improves the quality of life of hemodialysis patients.

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Manar Tarek Mostafa Morsy, BSc in physical therapy
  • Phone Number: +0201200469648
  • Email: drmtarekmali@gmail.com

Study Locations

      • Cairo, Egypt
        • Recruiting
        • Quweisna central hospital
        • Contact:
          • Manar Tarek Mostafa Morsy, BSc in physical therapy
          • Phone Number: +201200469648
          • Email: drmtarekmali@gmail.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Patients of both sexes diagnosed with ESRD (stage 5 CKD).
  2. Ages from 40 to 60 years.
  3. Patients on hemodialysis for at least one year with 2 to 3 sessions per week lasting 3 to 4 hours each.
  4. Their body mass index 25 - 34.9 kg/ m2 and under medical supervision.
  5. They are receiving HD though an uncomplicated arm arteriovenous (AV) fistula.
  6. They are in a stable medical, clinical and hemodynamic status.
  7. Individuals don't require lower limb dialysis grafting.

Exclusion Criteria:

  • 1- Patients with resting systolic blood pressure more than 200 mm Hg & or diastolic blood pressure greater than 120 mm Hg.

    2- Patients with uncontrolled diabetes mellitus, peripheral neuropathy, hepatic disorders (hepatic cancer, hepatitis) and infectious illness (HIV / AIDS).

    3- Patients with mental health problems and cognitive impairment owing to the inability to educate them how to perform relaxation techniques.

    4- Any patient who missed more than two weeks of the program or want to terminate the program.

    5- Severe Obesity (BMI> 35). 6- Patients had a previous history of psychiatric disorders. 7- Uncontrolled pulmonary disease (e.g. exaggerated acute asthma, exaggerated acute chronic obstructive lung disease).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Study group (benson's relaxation technique)

Thirty patients of both gender will receive Benson's relaxation technique 3 times / week for 12 weeks with duration 10-20 minutes at the end of second hour of dialysis session and aerobic exercise in addition to their medical treatment.

Research has shown that the Benson Relaxation Technique (BRT) is an effective strategy for decreasing sleep disruptions in older persons and hemodialysis patients with hypertension focuses on deep rhythmic breathing and mental focusing rather than physical muscle tensing. Steps :

1. Find a quiet environment: Sit or lie down in a comfortable, quiet space where you will not be disturbed. 2. Close your eyes: Gently close your eyes to block out visual distractions.3. Relax your muscles: Release all tension from your body, moving progressively from your feet up to your face (or top of your head).4. Breathe through your nose: Become aware of your natural breathing. As you exhale, silently repeat a chosen focus word or phrase-such as "one", "calm", or "peace"-to yourself (e.g., inhale... exhale, "one").5. Maintain a passive attitude: When distracting thoughts drift into your mind, do not fight them or judge yourself.6.Practice for 10 to 20 minutes7.Transition slowly

Active Comparator: Control group

Thirty patients of both gender will receive the same aerobic exercise in addition to their medical treatment.

Aerobic exercise: by using mini pedal bike for 12 weeks , 30 minutes in the first 2 hours of dialysis session

Aerobic ex by using mini pedal exerciser without involving benson's relaxation technique.

for 12 weeks , 30 minutes in the first 2 hours of dialysis session

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dialysis adequacy
Time Frame: 12 weeks

Dialysis adequacy will be assessed using URR (Urea Reduction Ratio) and KT/V measured pre- and post-intervention to determine the effectiveness of the treatment in improving hemodialysis efficiency.

12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Sleep Quality Measured by the Pittsburgh Sleep Quality Index (PSQI)
Time Frame: 12 weeks

Sleep Quality will be assessed by PSQI pre and post intervention to determine the effectiveness of (sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction)

12 weeks
Change in Anxiety Score Measured by the Hospital Anxiety and Depression Scale (HADS)
Time Frame: 12 weeks

Anxiety symptoms will be assessed using the anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A). Changes in anxiety scores will be compared between baseline and follow-up.

12 weeks
Change in Depression Score Measured by the Hospital Anxiety and Depression Scale (HADS)
Time Frame: 12 weeks

Depressive symptoms will be assessed using the depression subscale of the Hospital Anxiety and Depression Scale (HADS-D). Changes in depression scores will be compared between baseline and follow-up.

12 weeks
Change in Systolic and Diastolic Blood Pressure
Time Frame: 12 weeks

Systolic and diastolic blood pressure will be measured using a digital sphygmomanometer to assess changes in blood pressure following the intervention.

12 weeks
Change in Functional Performance Measured by the 2-Minute Walk Test (2MWT)
Time Frame: 12 weeks

Functional performance will be assessed using the 2-Minute Walk Test (2MWT), measured by the distance walked in meters during two minutes.

12 weeks
Change in Kidney Disease Quality of Life (KDQOL-36) Scores
Time Frame: 12 weeks

Health-related quality of life will be assessed using the Kidney Disease Quality of Life 36-item Short Form survey (KDQOL-36), including its kidney disease-specific and generic health-related quality-of-life domains.

12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

July 1, 2027

Study Completion (Estimated)

September 1, 2027

Study Registration Dates

First Submitted

November 9, 2026

First Submitted That Met QC Criteria

November 9, 2026

First Posted (Actual)

November 13, 2026

Study Record Updates

Last Update Posted (Actual)

November 13, 2026

Last Update Submitted That Met QC Criteria

November 9, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe